ORBi: Detailled Reference

Article (Scientific journals)

Existe-t-il une "memoire therapeutique" en prevention cardiovasculaire?

Scheen, André

2007 • In Revue Médicale Suisse, 3 (122), p. 1864-6, 1868-9

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/8992

PubMed
17896659

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

mmoire thrapeutique_ocr.pdf

Author postprint (67.8 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Antilipemic Agents/therapeutic use; Cardiovascular Diseases/prevention & control; Diabetes Mellitus, Type 2/prevention & control; Humans; Hypoglycemic Agents/therapeutic use; Life Style

Abstract :

[en] The prevention of type 2 diabetes and of cardiovascular diseases is a major public health objective. Obviously life-style changes play a major role in this strategy. The Finnish Prevention Study recently demonstrated that the remarkable diabetes prevention observed after a 4-year lifestyle intervention is maintained after a further 3-year period of follow-up without prolongation of the active intervention. Such a reminiscent effect may also be observed in the prevention of cardiovascular diseases with various pharmacological interventions: an ACE inhibitor (HOPE), a statin (4S), a fibrate (Helsinki Heart Study) or an intensive insulin therapy in type I diabetic patients (DCCT-EDIC). These intriguing results argue for a long-term memory of previous therapeutic interventions in cardiovascular prevention.

Disciplines :

Pharmacy, pharmacology & toxicology
Cardiovascular & respiratory systems

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Existe-t-il une "memoire therapeutique" en prevention cardiovasculaire?

Alternative titles :

[en] Does a "therapeutic memory" exist in cardiovascular prevention?

Publication date :

2007

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

3

Issue :

122

Pages :

1864-6, 1868-9

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http:/www.revmed.ch

Available on ORBi :

since 16 March 2009

Statistics

Number of views

194 (2 by ULiège)

Number of downloads

140 (0 by ULiège)

More statistics

Scopus citations^®

1

Scopus citations^®
without self-citations

0

Bibliography

Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-9.
Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-21.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 2005;112:2735-52.
Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005;352:1138-45.
Task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and the European society for the study of diabetes (EASD). Guidelines on diabetes, prediabetes and cardiovascular diseases: Executive summary. Eur Heart J 2007;28:88-136.
Scheen AJ. Comment j'explore ... les critères de jugement dans les essais cliniques: réflexion à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liège 2006;61:260-6.
Tuomilehto J, Lindström J, Ericksson JG, et al for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes meilitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
* Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9.
Scheen AJ. Antidiabetic agents in patients with mild dysglycaemia: Prevention or early treatment of type 2 diabetes? Diabetes Metab 2007;33:3-12.
The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6.
The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-105.
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-19.
Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004;64:2537-65.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
* HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes. Results of the HOPE study extension. Circulation 2005;112:1339-46.
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
Pedersen TR, Wilhelmsen L, Faergeman O, et al, on behalf of the Scandinavian Simvastatin Survival Study Group. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000;86:257-62.
* Strandberg TE, Pyörälä K, Cook TJ, et al, for the 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: What have we learned in the past 40 years? Pharmacotheray 2007;27:412-24.
Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-61.
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
* Tenkanen L, Manttari M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: An 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 2006;166:743-8.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
* The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type I diabetes. N Engl J Med 2005;353:2643-53.

Similar publications